ME Therapeutics Holdings Inc. Stock Deutsche Boerse AG

ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.